Cargando…
Sulfatinib, a novel multi-targeted tyrosine kinase inhibitor of FGFR1, CSF1R, and VEGFR1–3, suppresses osteosarcoma proliferation and invasion via dual role in tumor cells and tumor microenvironment
INTRODUCTION: Tumor progression is driven by intrinsic malignant behaviors caused by gene mutation or epigenetic modulation, as well as crosstalk with the components in the tumor microenvironment (TME). Considering the current understanding of the tumor microenvironment, targeting the immunomodulato...
Autores principales: | Liao, Song, Li, Jianxiong, Gao, Song, Han, Yuchen, Han, Xinli, Wu, Yanan, Bi, Jingyou, Xu, Meng, Bi, Wenzhi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10286821/ https://www.ncbi.nlm.nih.gov/pubmed/37361567 http://dx.doi.org/10.3389/fonc.2023.1158857 |
Ejemplares similares
-
A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors
por: Dasari, Arvind, et al.
Publicado: (2023) -
Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study
por: Xu, Jian Ming, et al.
Publicado: (2017) -
MicroRNA-124 functions as a tumor suppressor and indicates prognosis in human osteosarcoma
por: HAN, GANG, et al.
Publicado: (2015) -
Combination of IDO inhibitors and platinum(IV) prodrugs reverses low immune responses to enhance cancer chemotherapy and immunotherapy for osteosarcoma
por: Xiang, Dongquan, et al.
Publicado: (2023) -
VEGFR1-tyrosine kinase signaling in pulmonary fibrosis
por: Amano, Hideki, et al.
Publicado: (2021)